CVS Health's decision to withdraw Aetna's ACA plans by 2026 could leave nearly a million people in 17 states searching for ...

Even if the order takes effect, it will do nothing to address the root causes of the problem it purports to solve.

Eli Lilly's stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound. CVS Health said the drugs Wegovy and Saxenda from rival drugmaker Novo ...

Looking at surging obesity drug sales, market share momentum, and an increased fair value estimate, here’s what we think of ...

It's unclear how much the CVS formulary change will appeal to employers, especially given that Zepbound is known to be more effective at promoting weight loss than Wegovy ... Read the full ...

On Friday, the company’s health services unit Evernorth unveiled new programs in a reliable growth area: helping payers ...

CVS's decision to withdraw from the Affordable Care Act's individual markets could leave nearly a million Americans without ...

Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo ...

A million Affordable Care Act enrollees across 17 states will have to find alternate coverage in 2026. Separately, the Centers for Medicare & Medicaid Services now has a center to fight waste, fraud, ...

INDIANAPOLIS — Eli Lilly's stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound. CVS Health said the drugs Wegovy and Saxenda from rival ...

Eli Lilly and Company's stock dropped 11% after CVS's Zepbound exclusion, but analysts see a mispricing opportunity. Click for why LLY growth remains strong.